Dynavax Technologies Corporation
Dynavax Technologies — Investor Presentation (January 2023)
26 slides from Dynavax Technologies's investor presentation, Jan 9, 2023
Slide 1: Developing and Commercializing Innovative Vaccines
Developing and Commercializing Innovative Vaccines Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases January 2023 Nasdaq: DVAX Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the potential for HEPLISAV-B to become the mark
Slide 3: Dynavax at a Glance
Versatile proprietary adjuvant technology Commercial vaccine with continued growth potential and significant addressable market Differentiated vaccine development pipeline targeting large indications with unmet need Fully-integrated infrastructure supporting U.S. commercialization & global manufactu
Slide 4: Dynavax Core Strategic Priorities
Dynavax Core Strategic Priorities © Copyright DYNAVAX 2023 Drive Growth in Advance Differentiated Vaccine Pipeline Identify Strategic Opportunities to Accelerate Growth Increase market share to become the market leader by 2027 Maximize total addressable market based on the ACIP Universal Recommendat
Slide 5: Executing on Our Strategy: FY-2022 Preliminary Financial & Pipeline Highlights
Executing on Our Strategy: FY-2022 Preliminary* Unaudited Financial & Pipeline Highlights Preliminary* FY-2022 Financial Results © Copyright DYNAVAX 2023 Tdap Phase 1 completed; positive data presented in October 2022 Shingles Phase 1 initiated and completed; positive topline results reported in Jan
Slide 6: CpG 1018 Adjuvant: Well-defined MOA and Clinical Profile
CpG 1018® Adjuvant: Well-defined MOA and Clinical Profile Clinically Proven Profile Faster and consistently higher rates of protection in HEPLISAV-B, including in the elderly and populations less responsive to other vaccines Favorable tolerability profile Well-established safety, immunogenicity and
Slide 7: A Broad Vaccine Platform With High Potential
A Broad Vaccine Platform With High Potential Our proprietary CpG 1018 adjuvant is being used to support worldwide vaccine development for infectious diseases which take an increasing toll on public health CpG 1018 adjuvant powers our FDA approved vaccine Shingles Tdap (pertussis) Pre-clinical Plague
Slide 8: Diversified Pipeline Leveraging CpG 1018 Adjuvant
Diversified Pipeline Leveraging CpG 1018 Adjuvant © Copyright DYNAVAX 2023 U.S. Department of Defense Wholly owned by Dynavax Serum Institute of India US, EU and private market commercial rights owned by Dynavax Wholly owned by Dynavax Commercial Products Hepatitis B PRE-CLINICAL PHASE 1 PHASE 2 PHA
Slide 9: Commercial Product
Commercial Product © Copyright DYNAVAX 2023 9 |
Slide 10: There is No Cure for Hepatitis B, Prevention is Essential
There is No Cure for Hepatitis B, Prevention is Essential Hepatitis B is an incurable liver infection caused by the hepatitis B virus transmitted by bodily fluids. When the virus attacks the liver, the resulting health complications can be lifelong or even deadly. © Copyright DYNAVAX 2023 1 out of 3
Slide 11: HEPLISAV-B Clinical Outcomes
HEPLISAV-B Clinical Outcomes Higher and faster rates of protection HEPLISAV-B provided significantly higher rates of protection than Engerix-B at every time point in clinical trials HEPLISAV-B provided significantly higher rates of protection in diabetics and other known hypo-responsive populations
Slide 12: Hepatitis B Market Opportunity
Hepatitis B Market Opportunity © Copyright DYNAVAX 2023 Millions of Adults 209M 88M 73M 133M *Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvacc
Slide 13: IDN and Retail are the Largest Growth Segments
Integrated Delivery Networks (IDN) and Retail are the Largest Growth Segments © Copyright DYNAVAX 2023 HEPLISAV-B is the Market Leader in IDN/Large Clinics – A Segment that will Drive Meaningful Growth from the ACIP Universal Recommendation 2027 Projected Market Size $800M2 IDN/ Large Clinics4 “Fiel
Slide 14: Continued Growth in HEPLISAV-B Vaccine Market Share
Continued Growth in HEPLISAV-B Vaccine Market Share 33% Dialysis1 Centers 9% HEPLISAV-B Vaccine Market Share2 Source: Internal Data and company estimates. Market Segments by dose distribution reflects Q4 2020, Q4 2021 and Q4 2022. Not independently verified. 1 Based on 2022 U.S. adult hepatitis B va
Slide 15: Vaccine Development
Vaccine Development Tetanus, Diphtheria, and Pertussis (Tdap) | Herpes Zoster (Shingles) | Plague © Copyright DYNAVAX 2023 15 |
Slide 16: High Unmet Need for Addressing Resurgence of Pertussis
High Unmet Need Exists for Addressing Resurgence of Pertussis Globally ~24 million cases of pertussis2 160,700 Tetanus and diphtheria are rare, but pertussis continues to spread.1 deaths2 Globally In the U.S. Since 1991, when acellular pertussis vaccines replaced whole-cell vaccines, whooping cough
Slide 17: DV2-TDAP-01: Tdap Booster Vaccine
DV2-TDAP-01: Tdap Booster Vaccine Phase 1 Competitive efficacy and safety profile emerging Update and Next Steps: Phase 1 clinical results were presented in October 2022: Adult and adolescent safety data demonstrated the Tdap vaccine candidate was well tolerated without safety concerns. Immunogenici
Slide 18: Current Market-Leading Shingles Vaccine Associated with Adverse Events
Current Market-Leading Shingles Vaccine is Associated with Adverse Events1 – New Vaccine Options Needed Herpes Zoster (shingles) is an extremely painful consequence of the reactivation of a latent varicella-zoster virus (VZV), the same virus that causes varicella (chickenpox). In the U.S. Herpes zos
Slide 19: DV2-ZOS-01: Shingles Vaccine
DV2-ZOS-01: Shingles Vaccine Phase 1 Opportunity to improve vaccine tolerability while maintaining comparable efficacy © Copyright DYNAVAX 2023 We believe CpG 1018 adjuvant MOA is ideal for an improved shingles vaccine due to its ability to generate high levels of CD4+ T cell responses, which is key
Slide 20: Plague Remains a Threat to Humankind
Plague Remains a Threat to Humankind Plague is an infectious disease that can become severe if left untreated. As seen with the 2022 Mpox (monkeypox) outbreak, rare diseases that are endemic in remote parts of the world can suddenly spread and become a global threat. Government agencies research and
Slide 21: DV2-PLG-01: Plague Vaccine
DV2-PLG-01: Plague Vaccine Phase 2 Contract © Copyright DYNAVAX 2023 Update and Next Steps: Phase 2 clinical trial – Conducted in collaboration with, and funded by, the U.S. Department of Defense MOA has potential to speed up time to protection with fewer doses compared to the 3-dose vaccine under d
Slide 22: COVID-19 CpG 1018 Adjuvant Supply Business
COVID-19 CpG 1018 Adjuvant Supply Business © Copyright DYNAVAX 2023
Slide 23: Continued Public Health Focus Despite Pandemic to Endemic Transition
Continued Public Health Focus Despite Pandemic to Endemic Transition Despite incredible progress, unmet needs remain in COVID-19 as the pandemic continues, with a significant portion of the world population remaining unvaccinated. COVID-19 >657 million cases1 Of COVID-19 have been confirmed >28%4 Of
Slide 24: Well-positioned to Support Evolving Endemic COVID-19 Market
Well-positioned to Support Evolving Endemic COVID-19 Market Significant safety, efficacy and immunogenicity data for CpG 1018 adjuvant generated across multiple antigen platforms Minimal CpG 1018 adjuvant demand expected from customers in 2023 due to inventory on hand Additional potential demand for
Slide 25: Propelling Future Growth
Propelling Future Growth © Copyright DYNAVAX 2023 25 |
Slide 26: Delivering on Dynavax's Value Proposition
Delivering on Dynavax’s Value Proposition © Copyright DYNAVAX 2023 Focused on Commercial Business and Clinical Pipeline Building on Key 2022 Accomplishments 2023 Outlook HEPLISAV-B preliminary net sales of $126 million (104% Y/Y growth) Strengthened financial profile through successful execution COV
Dynavax Technologies — Investor Presentation (January 2023) on 6ix